Latest posts from
What is New in Respiratory Medicine
Facebook Group
-
Tuesday 21 Jul 2020
Risk assessment of COVID-19 patients in a quantitative, nonsubjective way is extremely important for the management of individual patients and for
-
Tuesday 21 Jul 2020
Un equipo del Instituto de Medicina Basada en la Evidencia de las universidades australianas de Bond y Sídney ha seleccionado los 14 mejores estudios de entre los 837 identificados en las bases PubMed, Embase, Cochrane y Europe-PMC desde enero de 2020 hasta el 25 de mayo de 2020. Los estudios provienen de 10 países y acumulan 100.557 personas: 9 eran preimpresiones, 3 estudios publicados y 2 informes gubernamentales. Hay 2 de Brasil, 2 de España (el del Hospital Clínic de Barcelona y el de prevalencia nacional con 61.000 analizados), 2 de Estados Unidos, 2 de Alemania, y uno de Italia, Croacia, Irán, Luxemburgo, Suiza y la isla británica de Jersey).
La seroprevalencia del SARS-CoV-2 es globalmente menor al 10%, lo que sugiere, como han apuntado otros análisis, niveles muy por debajo de la inmunidad colectiva.
Los datos más fiables indican una extensión mundial no muy alta, pero también una gran infradetección de contagiados.
-
Monday 20 Jul 2020
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized COVID-19 Patients
Some positive observational data on tocilizumab for the cytokine release syndrome associated with Covid-19 - as expected the authors conclude that RCTs are needed
Conclusion: A treatment algorithm that included tocilizumab to target CRS may influence MV and survival outcomes. In tocilizumab-treated patients, oxygenation and inflammatory biomarkers improved, with higher than expected survival. Randomized trials must confirm these findings.
A treatment algorithm that included tocilizumab to target CRS may influence MV and survival outcomes. In tocilizumab-treated patients, oxygenation and inflammatory biomarkers improved, with higher than expected survival. Randomized trials must confirm these findings.
-
Monday 20 Jul 2020
La reacción y respuesta es diferente según la gravedad de la enfermedad, esto es muy importante para hacer los estudios de vacunas que causen la mejor inmunidad que es la inmunidad celular. Podremos modificar esa inmunidad con los tratamientos actuales?
El coronavirus desencadena diferentes respuestas inmunitarias y síntomas en los pacientes graves, pero hasta ahora no se entiende bien cómo se relacionan esos dos factores, lo que dificulta las decisiones sobre el tratamiento
-
Monday 04 May 2020
Eight ways in which scientists hope to provide immunity to SARS-CoV-2 .
-
Monday 04 May 2020
Very interesting report to differentiate HAPE from SARS-COV-2 from BMJ.
"The use of medications for high altitude illness to treat covid-19 is likely to be unhelpful and could have a potentially dangerous outcome"
-
Monday 04 May 2020
Microbiome analysis of sputum reveals distinct endotypes of COPD with different inflammatory profiles and long term survival.
-
Monday 04 May 2020
“Late breaking abstracts open for @EuroRespSoc congress In Assembly 10 (infections) We have open slots for high profile oral presentations on bronchiectasis, pneumonia and the lung microbiome - so get your best work in now!! (don’t tell anyone i told you.......) https://t.co/St8p0pctKT”
-
Monday 04 May 2020
The city of Wuhan, in Hubei province, China is the focus of global attention due to the coronavirus disease 2019 (COVID-19) outbreak [1]. Sichuan, as a province near Hubei, also has been involved. As of February 12, 2020, 59 741 confirmed cases of COVID-19 have been reported in China, of which 451...
-
Sunday 03 May 2020
High vs. Low Dose Chloroquine COVID-19
The preliminary findings of this study suggest that the higher CQ dosage should not be recommended for critically ill patients with COVID-19 because of its potential safety hazards, especially when taken concurrently with azithromycin and oseltamivir. These findings cannot be extrapolated to patients with nonsevere COVID-19.
This randomized clinical trial evaluates the safety and efficacy of 2 chloroquine diphosphate dosages in patients with severe coronavirus disease 2019 (COVID-19).
-
Sunday 03 May 2020
Am I Part of the Cure or Am I Part of the Disease? Keeping Coronavirus Out When a Doctor Comes Home
( https://www.nejm.org/doi/full/10.1056/NEJMp2004768 )
Times like this can leave physicians stranded between our commitment to the community and responsibility to our families — a no man’s land where a colleague’s spare bed may be the closest approximation of home that we can find.
Perspective from The New England Journal of Medicine — Am I Part of the Cure or Am I Part of the Disease? Keeping Coronavirus Out When a Doctor Comes Home
-
Sunday 03 May 2020
What is a safe distance when running, biking and walking during COVID-19 times? It is further than the typical 1–2 meter as prescribed in…
-
Saturday 02 May 2020
Spironolactone and other androgen blockers might actually protect against the virus, according to a report in the Journal of the American Academy of Dermatology.
-
Saturday 02 May 2020
"It is too early to know what the long-term consequences of covid-19 will be"
-
Saturday 02 May 2020
#JACCINT Editors' Insights: In an early feasibility analysis, intravascular ultrasound pulmonary artery denervation for pulmonary artery hypertension was associated with:
No procedure-related adverse events Reduction in pulmonary vascular resistance *Increase in six minute walk test & daily activity Learn more from the TROPHY1 study: https://bit.ly/2SmrtOB
-
Saturday 02 May 2020
COVID-19 Related Genes in Sputum Cells in Asthma: Relationship to Demographic Features and Corticosteroids
From the National Heart, Lung, and Blood Institute (NHLBI) Severe Asthma Research Program (SARP)-3 Investigators
Higher expression of ACE2 and TMPRSS2 in males, African Americans, and patients with diabetes mellitus provides rationale for monitoring these asthma subgroups for poor COVID19 outcomes.
The lower expression of ACE2 and TMPRSS2 with ICS use warrants prospective study of ICS use as a predictor of decreased susceptibility to SARS-CoV-2 infection and decreased COVID19 morbidity.
Background: Coronavirus disease 2019 (COVID-19) is caused by SARS-coronavirus 2 (SARS-CoV-2). Angiotensin converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2) mediate viral infe...
-
Saturday 02 May 2020
ATS/ERS Joint Webinar on Global Perspective on COVID-19
ATS and ERS Joint Webinar: Global Perspectives on COVID-19: Italy, France, Germany and the United States (NY).
-
Saturday 02 May 2020
Chitotriosidase (CHIT1) is a highly conserved and regulated chitinase secreted by activated macrophages; it is a member of the 18-glycosylase family (GH18). CHIT1 is the most prominent chitinase in humans, can cleave chitin and participates in the body's immune response and is associated with inflam...
-
Saturday 02 May 2020
An “FDA/approved” drug for severe COVID-19 This is not the formal process, but an emergency nod due to the lethal nature of the disease Let’s hope that in the long run remdesivir will prove to be efficacious...
Days after U.S. officials reported the first positive controlled data for Gilead's remdesivir in COVID-19, the FDA has given the drug an emergency use authorization.
-
Friday 01 May 2020
Experts say at least 18 months. Here’s how to shorten the timeline.
